Gastroduodenal tolerability of medium dose enteric‐coated aspirin: a placebo controlled endoscopic study of a new enteric‐coated formulation versus regular formulation in healthy volunteers

Abstract

We compared, in a cross-over study, the toxicity of 300 mg enteric-coated aspirin with regular aspirin used for the prevention of cardiovascular events. In terms of endoscopic haemorrhagic lesions, enteric-coated aspirin is less gastrotoxic than regular aspirin.

Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy

“…Moreover, it is also important to confirm the difference of small intestinal toxicity between the different formulations of aspirin. Some studies have demonstrated that enteric-coated aspirin caused fewer gastroduodenal injuries than regular aspirin [22,23]; however, the difference in small bowel toxicity between these two formulations is unknown. Our report showed that the proportion of subjects with small bowel ulcer was increased in patients taking enteric-coated aspirin compared with those taking regular aspirin (56.3 vs. 16.7%).…”

Incidence of Small Bowel Injury Induced by Low-Dose Aspirin: A Crossover Study Using Capsule Endoscopy in Healthy Volunteers

“…Fourth, our results might be affected by the formulation of aspirin. Enteric-coated aspirin causes less gastroduodenal injuries than regular aspirin [26, 27]. Considering that the small bowel proximal segment as defined by this study included the duodenal bulb, the formulation of aspirin might influence the distribution of the small bowel injuries.…”

Toxicity and Drug Safety

“…Although these data were confirmed by many other studies, usually small endoscopic studies in man [146,[229][230][231][232][233][234][235], they cannot rule out a bleeding risk that is (by definition) associated with the clinical use of aspirin in cardiocoronary prevention (see below). Importantly, the inhibition of platelet-dependent thromboxane formation and platelet function does not differ between enteric-coated and plain aspirin at doses of 100 mg/day or above [173].…”